Home >> Expert Review of Vaccines, Volume 5, Number 5

Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials

Authors: Mossoba, Miriam E; Medin, Jeffrey A

Source: Expert Review of Vaccines, Volume 5, Number 5, October 2006 , pp. 717-732(16)

Publisher: Expert Reviews

Buy & download fulltext article:

OR

Price: $73.00 plus tax (Refund Policy)

Abstract:

The immune system uses a process known as `immunosurveillance' to help prevent the outgrowth of tumors. In cancer immunotherapy, a major goal is for immunity against tumor-associated antigens to be generated or strengthened in patients. To achieve this goal, several approaches have been tested, including the use of highly potent antigen-presenting cells called dendritic cells (DCs), which can activate T cells efficiently. Presentation of peptides derived from tumor antigens on the surface of DCs can stimulate strong antitumor immunity. Using recombinant viral vectors encoding tumor-associated antigens, DCs can be engineered efficiently to express sustained levels of tumor-antigen peptides. This review discusses the effectiveness of virally transduced DCs in treating tumors and generating antigen-specific T-cell responses. It covers mouse and nonhuman primate studies, preclinical in vitro human cell experiments and clinical trials.
More about this publication?
Related content
Marked list

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
^ Back to top
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page